Long Term Extension Trial of Setmelanotide

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

July 15, 2018

Primary Completion Date

January 9, 2025

Study Completion Date

January 9, 2025

Conditions
Obesity Associated With Defects in Leptin-melanocortin Pathway
Interventions
DRUG

Setmelanotide

Once daily subcutaneous injection

Trial Locations (27)

13354

Charité - Universitätsmedizin Berlin, Berlin

14203

University at Buffalo, Buffalo

19104

Childrens Hospital of Philadephia, Philadelphia

26504

University General Hospital of Patras, Rio

27612

Wake Research, Raleigh

27705

Duke University Medical Center, Durham

29621

Synexus Clinical Research US, Inc.- Primary Care Associates, PC, Anderson

32610

University of Florida College of Medicine, Gainesville

37212

Vanderbilt University Medical Center, Nashville

37421

Wake Research TN, Chattanooga

54449

Marshfield Clinic Research Institute, Marshfield

75012

Hôpital Trousseau, Paris

75013

Hôpital de la Pitié Salpêtrière, Paris

85224

Synexus Clinical Research US, Inc. - Phoenix Southeast, Chandler

85258

Honor Health Research Institute, Scottsdale

89075

University of Ulm, Ulm

92108

San Diego Wake Research, San Diego

98101

Seattle Children's Research Institute, Seattle

01107

Baystate Medical Center, Springfield

17822-2607

Obesity Institute, Geisinger Clinic, Danville

T6G 2E1

University of Alberta, Edmonton

04103

University of Leipzig, Leipzig

Unknown

Erasmus MC, Rotterdam

65 28009

Universidad Autónoma de Madrid, Madrid

B15 2GW

University Hospitals Birmingham NHS Foundation Trust, Birmingham

CB2 0QQ

Wellcome Trust-MRC Institute of Metabolic Science, Cambridge

W12 0NN

Hammersmith Hospital, London

All Listed Sponsors
lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY

NCT03651765 - Long Term Extension Trial of Setmelanotide | Biotech Hunter | Biotech Hunter